Weekly Vaccine Digest 10/13

County of Los Angeles, California sent this bulletin at 10/13/2023 04:08 PM PDT

Weekly Vaccine Digest 10/13

Los Angeles County Department of Public Health

Dear Colleagues and Partners,   

Below are the LACDPH weekly vaccine administration and order updates, upcoming webinars, and newsworthy events. Attached to this email you will find a pdf version of this digest and the links shared during the LA DPH and CDPH Office Hours. To view the CDPH recording and slides please visit https://eziz.org/.  Bridge Access Program COVID vaccine inventory supply remains extremely limited. Please order small quantities and you can order on a weekly basis. Orders will be reduced or rejected based on our available inventory.

 

If you received this email and would like to be added to our listserv, please contact our COVID-19 Provider Vaccine Call Center at covidvaccinereq@ph.lacounty.gov

 

Table of Contents

•

Page 1-6: Order and Administration Reminders, Respiratory Syncytial Virus (RSV), Nirsevimab: Dosing and Timing of Administration

•

Page 6-7 Upcoming Webinars, Novavax Update

•

Page 8: myCAvax Release 44, Bridge Access Program

•

Page 9: LACDPH & CDPH Provider Office Hours Link

 

Order and Administration Reminders

  • REMINDER: Please place all State General Flu (SGF) orders in myCAvax by 5pm on Monday, 10/16. See Ordering and Distribution Cadence Calendar for more information. Please note that DPH is also filling SGF orders through local fulfillment.
  • REMINDER: Please place all BAP orders in myCAvax by 5 pm on Monday, 10/16. CDPH has distributed additional doses to support provider requests. When inventory becomes limited, orders may be cancelled or reduced.
  • Order a 1-2 week supply of vaccine for flu and BAP and order weekly as necessary.
  • Vaccine delivered from the DPH warehouse will be delivered 3-7 business days after the order is place in myCAvax. Please present a photo ID (work badge, school ID, driver’s license, etc.) and sign for the delivery when received.
  • REMINDER: Job aid for Vaccine and Clinic Eligibility by Funding Source can be found here. 

______________________________________________________


Respiratory Syncytial Virus (RSV)

  • NEW: Visit CDPH’s new Respiratory Virus webpage here. 
  • NEW: Find RSV Immunization Resources here
  • Clinical Guidance: RSV Immunizations
    • 2023 CDC Immunization Schedules Update
      • CDC Immunization Schedules typically updated in February
      • New addenda summarize recommendations adopted in 2023 for COVID19, RSV, poliovirus, and influenza:
        • Recommended Child and Adolescent Immunization Schedule, United States, 2023
        • Recommended Adult Immunization Schedule, United States, 2023
      • By publishing updated official schedules now, CDC reduces the time between new recommendations and insurance coverage for the new recommendations, as required by the Affordable Care Act.
  • RSV Immunization Products Overview
    • Infants and Toddlers
      • One dose of nirsevimab is recommended for all infants younger than 8 months of age who are born during —or entering — their first RSV season
      • One dose of nirsevimab is recommended for infants 8 through 19 months of age who are at higher risk of severe disease shortly before, or during, their second RSV season.
    • Pregnant People
      • RSV vaccine administered between 32 – 36 weeks of pregnancy, between September-January
      • Maternal RSVpreF vaccine may be simultaneously administered with other recommended vaccinations during pregnancy (Tdap, Flu, COVID-19)
    • Older Adults
      • Adults 60 years and older may be eligible for an RSV vaccine, under shared clinical decision making with their health care provider

Image 1

  • RSV Vaccines Approved for Adults Ages ≥ 60 Years Single dose, Intramuscular Injection Infants and Toddlers

Image 2

  • RSV Vaccines for Older Adults: Safety

Image 3

  • Older Adult RSV Vaccine Recommendations
    • Adults aged 60 years and older may receive a single dose of RSV vaccine, using shared clinical decision-making.
    • Give as early as vaccine supply becomes available and continue to offer vaccination to eligible adults who remain unvaccinated.
    • Co-administration of RSV vaccines with other adult vaccines during the same visit is a recommended option.
  • Shared Clinical Decision-Making Guidance can be found here.
  • RSV Immunizations to Protect Infants & Toddlers
    • CDC Recommends RSV Vaccine for Pregnant People
      • RSV vaccine (RSVpreF, ABRYSVOTM) is recommended for pregnant people at 32 through 36 weeks of pregnancy during the months of September through January to prevent RSV infections in their infants.
      • People can receive the RSV vaccine on the same day as other vaccines recommended during pregnancy, including Tdap, COVID-19, and influenza.
      • Most infants will likely only need protection form either the prenatal RSV vaccine or infant immunization, but not both.
      • Healthcare providers of pregnant people should provide information on both products and consider patient preferences when determining whether to vaccinate the pregnant patient.
  • RSV Immunization for Infants and Toddlers
    • An RSV immunization called nirsevimab (BeyfortusTM) can help protect infants and toddlers from severe RSV illness. 
    • The antibodies in nirsevimab are just like those that develop after a typical vaccine. 
    • RSV immunization is recommended for: 
      • All infants aged < 8 months born during or entering their first RSV season, including those recommended by the AAP to receive palivizumab.
      • Infants and children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season, including those recommended by AAP to receive palivizumab

______________________________________________________

Nirsevimab: Dosing and Timing of Administration

  • Dose depends on age and weight
  • Infants born shortly before and during the RSV season should receive nirsevimab within the first week of life, including in hospital settings.
  • Offer nirsevimab now, as soon as supplies become available.
  • Protection is expected to last at least 5 months, about the length of an RSV season
  • Co-administration of nirsevimab with other routine pediatric vaccines during the same visit is a recommended option
  • The Nirsevimab Guide can be found here.
  • Nirsevimab: 8 -19-Month-Old High-Risk Eligibility Criteria
    • Chronic lung disease (CLD) of prematurity who required medical support at any time during the 6 months (steroids, diuretics, oxygen) before the start of RSV season. 
    • Severe immunocompromise
    • Cystic fibrosis who have either 1) severe lung disease or 2) weight for length.
    • American Indian and Alaska Native children (this group is newly recommended in contrast to current palivizumab recommendations).
    • Detailed information on palivizumab eligibility can be found in AAP Red Book and the 2014 guidance for palivizumab for RSV prophylaxis.
  • Nirsevimab: Frequently Asked Questions can be found here.
  • Efficacy of RSV Immunizations to Protect Infants

PICTURE 4

  • RSV Immunization Safety
    • Prenatal RSV Vaccine 
      • In the clinical trials, the side effects most often reported by pregnant people were pain at the injection site, headache, muscle pain, and nausea.
      • Pre-eclampsia occurred in 1.8% of pregnant people who received the RSV vaccine compared to 1.4% of pregnant people who received a placebo.
      • The clinical trials identified a small increase in the number of preterm births in vaccinated pregnant people. It is not clear if this is a true safety problem related to RSV vaccine or if this occurred for reasons unrelated to vaccination.
    • Nirsevimab
      • Side effects after nirsevimab were uncommon in clinical trials. The most common side effects are pain, redness, or swelling at the injection site, and a rash. No serious allergic reactions occurred in the clinical trials
  • Reporting Adverse Events
    • Report adverse events following vaccination to VAERS
    • Nirsevimab considerations:
      • Report side effects that happen after getting nirsevimab to the MedWatch website or by calling 1-800-FDA-1088. 
      • If a child also received any vaccine on the same day as nirsevimab, the side effects also may be reported to VAERS.
  • RSV Vaccine Insurance Coverage
    • RSV Vaccine Covered by Medi-Cal & Medicare Part D
    • Currently covered only as a pharmacy benefit currently for Medi-Cal & Medicare Part
    • Managed Medi-Cal may possibly be covered in MD office per plan.

Image 5 

______________________________________________________ Upcoming Webinars

 

  • Webinar: Respiratory Syncytial Virus (RSV
    • When: Monday October 16, 2023 12pm-1pm. Registration link can be found here.
  • Crucial Conversations Webinar: Talking with Patients about the Fall COVID-19, Flu, and RSV Season
    • When: Wednesday October 18, 2023 12pm-1pm. Registration link can be found here.
  • SGF Flu Vaccine Management 102 for Providers
    • When: Monday October 23, 2023 12pm-1pm. Registration link can be found here.
  • Bridge Access Program myCAvax Office Hours
    • When: Thursday October 26, 2023 11am-11:30am. Registration link can be found here.
  • STI Clinical Update Webinar: California Mpox Update for Healthcare Providers
    • When: Thursday, October 26, 2023 Time: 12PM – 1PM, PDT Register here.
  • Nirsevimab implementation strategies in outpatient practices (AAP)
    • When: Tuesday, October 17, 2023, at 5PM, PST – Register here
  • Clinical Update on the 2023 Respiratory Virus Season (CDC Current Issues in Immunization Webinar)
    • When: Wednesday, October 18, 2023. Time: 9:00am-10:00am – Registration is not needed. Join the webinar here.

______________________________________________________

Novavax Update

  • Novavax 2023-2024 COVID-19 Vaccine Now Authorized
    • Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA COVID-19 vaccine) are eligible to receive one dose at least 2 months after their last dose.
    • Unvaccinated individuals are eligible receive two doses.
    • Immunocompromised individuals are eligible for an additional dose of Novavax COVID19 Vaccine, Adjuvanted (2023-2024 Formula) at least 2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula). Additional doses of Novavax COVID19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at the discretion of the healthcare provider,
    • Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent) is no longer authorized for use in the United States and should no longer be used.
  • Novavax Vaccine Resources
  • What to Do with Deauthorized Novavax Vaccine
    • Quarantine deauthorized Novavax vaccine to prevent administration errors!
    • Report doses as “Waste” in myCAvax and use “Other” to add comment “deauthorized”!
    • Dispose of vaccines following practice protocols; vaccines may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps waste 
    • container!
  • My Turn added the recently authorized Novavax product and mapped the current vaccine supply to this product on Wednesday, October 11, 2023. Please update your clinic vaccine inventory and de-activate the deauthorized Novavax inventory.
    • NOTE: If you remove the de-authorized inventory, historical bulk upload will not be available for that clinic.
  • Commercial purchase of Novavax

______________________________________________________

 myCAvax Release 44 (October 20, 2023)

  • myCAvax R44 is the last scheduled production release until February 2024. There may be ad-hoc releases for key system updates as needed.
  • My Turn production releases will continue their usual monthly cadence. Updates will be shared at our weekly webinars for both platforms as usual.
  • Expanded SGF Capabilities
    • Be able to record temperature excursions for SGF vaccines and select products on
    • ‘Excursion’ pop-up window based on the program selected
    • Be able to record waste events for SGF vaccines and select products on the ‘New Waste Report’ pop-up window based on the program selected
    • Receive LHD initiated SGF transfers
  • Provider Community Site
    • See the new BAP logo on the program tile on the landing page
    • See a dropdown on the SGF program tile with new site functionalities for the SGF program
    • See an updated ‘State General Fund - Home’ page with new site functionalities
    • See Program Locations on the ‘Locations’ page based on the program selected
    • See the new ‘Program Type’ picklist on the COVID-19 ‘Shipment Incidents’ and ‘Orders’ pages
    • See the new ‘USG COVID-19 Program’ checkbox on the COVID-19 Program Location applications and related lists of COVID-19 Program Locations
    • See relabeled shipping address fields on the Location Account form
  • NOTE: On Friday, October 20, 2023, the ‘Vaccine Administration Address’ field will be removed from myCAvax. To comply with CDC policy, providers must be prepared to receive vaccine shipments at the same address in which they are administering vaccine, and the shipping address listed on their Location Accounts must be used for all Program Locations.
    • PROVIDERS MUST: Providers, if you need to update your shipping address to comply with the single shipping address requirement, contact the Provider Call Center at providercallcenter@cdph.ca.gov or (833) 502 - 1245. Note that the secondary address line may be customized at each Program Location to specify a specific suite, building, etc. Be sure to confirm your shipping hours

______________________________________________________

Bridge Access Program

Bridge Access Program Retail Pharmacies

  • Work directly with eTrueNorth to enroll your pharmacy location in the Bridge Access Program.
  • eTrueNorth makes participation easy by providing a secure online platform for convenient patient sign-up and participating pharmacy reimbursement.
  • Interested pharmacies can visit Enrolling Bridge Access Program: joinetruenoth.com
  • The pharmacy component of the Bridge Access Program acts on a reimbursement model
    • This differs from the public health component which used a separate stock provided via allocation.
    • There is NOT a separate BAP inventory supply for pharmacies.
    • Commercial products will be purchased and then be reimbursed. eTrueNorth will reimburse for the invoiced cost of the vaccine and CDC will reimburse the $40 admin fee
    • More information is in the onboarding packet from eTrueNorth

______________________________________________________

LACDPH & CDPH Provider Office Hours Link

LA County Department of Public Health Provider Immunization Office Hours Information

  • Every other Wednesday from 9am-10am - Next meeting: 10/25/23
    • NOTE: Effective 2/01/23 the Office Hours will be held on a biweekly basis
  • This has been meeting amended to discuss COVID, Mpox, Flu and RSV vaccines. The meeting link will remain the same.
  • MS Teams meeting link below; please create a recurring calendar invite with this link.
  • To request meeting slides, please email covidvaccinereq@ph.lacounty.gov

Microsoft Teams meeting
Join on your computer or mobile app 
Click here to join the meeting

Or call in (audio only)

+1 323-776-6996,,350547595# United States, Los Angeles

California Department of Public Health Provider Office Hours Registration Link

  • Every Friday from 9am-10:30am.
  • Complete one-time registration here.
  • Meeting recordings and slides can be found here.

Providers should add staff names to the Provider Listserv to receive weekly emails and updates. To be added, please email blanca.corona@cdph.ca.gov